Physician profile
David M Blake
NPI 1295837094
$3,311.35
in general payments reported to CMS, 2019-2025
28 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $972 · 2020: $491 · 2021: $655 · 2022: $344 · 2023: $220 · 2024: $400 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $849.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $690.38 | 2021-2025 | Qulipta, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $522.73 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $255.97 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $206.88 | 2021 | |
| Biogen, INC. | $196.40 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $193.50 | 2019-2021 | |
| Amgen INC. | $187.44 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $132.68 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.99 | 2025 | Hyqvia |
| Genentech USA, INC. | $122.39 | 2019 | |
| Genentech, INC. | $113.25 | 2019-2023 | Ocrevus |
| Alexion Pharmaceuticals, INC. | $109.17 | 2019 | |
| Ucb, INC. | $97.85 | 2019 | |
| Janssen Pharmaceuticals, INC | $60.00 | 2022 | |
| Pfizer INC. | $52.02 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $31.35 | 2024 | Gamunex-C |
| Medtronic Vascular, INC. | $25.82 | 2019 | |
| Acorda Therapeutics, INC | $25.71 | 2019 | |
| Amneal Pharmaceuticals LLC | $25.41 | 2019-2024 | Rytary |
| Allergan, INC. | $23.13 | 2020 | |
| Celgene Corporation | $22.15 | 2021 | |
| Kyowa Kirin, INC. | $20.90 | 2024 | Nourianz |
| Scilex Pharmaceuticals INC. | $19.03 | 2024 | |
| Neurocrine Biosciences, INC. | $16.41 | 2023 | Ongentys, Ingrezza |
| Vanda Pharmaceuticals INC. | $15.39 | 2024 | Ponvory |
| Cook Medical LLC | $13.70 | 2021 | |
| Aucta Pharmaceuticals, INC. | $5.87 | 2025 | Motpoly Xr |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Blake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.